Healthcare / BiotechnologyNasdaqCM
$13.43
-3.00 (-18.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-12.6M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$15M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-61.1%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-17.3M · FCF $-10.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Net Income | $-17.3M | $-17.3M | $-19.8M | $-10.0M | $-17.7M | $-45.3M | $-1.9M | $-3.6M | $-4.3M |
| EBITDA | $-17.4M | $-17.4M | $-19.5M | $-10.0M | $-23.1M | — | — | — | — |
| EPS | — | — | — | — | -216.00 | — | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | 0.03 | 0.03 | 0.15 | — | — | — | — | — | — |
| Current Ratio | 0.27 | 0.27 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-10.6M | $-10.6M | $-12.6M | $-16.4M | $-21.5M | $-5.0M | $-1.5M | $-5.5M | $-2.1M |
| Returns | |||||||||
| ROE | -61.1% | -61.1% | -89.0% | 4370.3% | -991.0% | -93.0% | -87.6% | -903.4% | 127.0% |
| Valuation | |||||||||
| P/B | 0.40 | 0.40 | 0.70 | — | 18.30 | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-75.1%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
-75.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.